Insomnia anxiety with, treatment

A dramatically different pattern is found in surveys of drug abuse treatment facilities. Substance abuse treatment centers have reported that more than 20% of patients use benzodiazepines weekly or more frequently, with 30%— 90% of opioid abusers reporting illicit use (Iguchi et al. 1993 Stitzer et al 1981). Methadone clinics reported that high proportions ofurine samples are positive for benzodiazepines (Darke et al. 2003 Dinwiddle et al. 1996 Ross and Darke 2000 Seivewright 2001 Strain et al. 1991 Williams et al. 1996). The reasons for the high rates of benzodiazepine use in opioid addicts include self-medication of insomnia, anxiety, and withdrawal symptoms, as well as attempts to boost the euphoric effects of opioids. 

Adverse reactions include nausea, nervousness, headache, insomnia, anxiety. Sexual dysfunction with loss of libido is a common complaint. Insomnia can be a problem. Urticaria and rashes have been described. Venlafaxine may significantly increase the risk of suicide and is therefore not recommended as a first line treatment of depression. The view that also fluoxetine and other SSRIs can lead to suicide is under debate for quite some time now. In most countries SSRIs are not approved for use in pediatric populations. In the UK and in the USA only fluoxetine can be prescribed for children. 

Other bad news in the treatment of depression is that many responders never remit (Table 5 — 17). In feet, some studies suggest that up to half of patients who respond nevertheless fail to attain remission, including those with either apathetic responses" or anxious responses (Table 5 — 18). The apathetic responder is one who experiences improved mood with treatment, but has continuing lack of pleasure (anhedonia), decreased libido, lack of energy, and no zest. The anxious responder, on the other hand, is one who had anxiety mixed with depression and who experiences improved mood with treatment but has continuing anxiety, especially generalized anxiety characterized by excessive worry, plus insomnia and somatic symptoms. Both types of responders are better, but neither is well. 

The short-acting barbiturates are used for short-term treatment of insomnia, anxiety, psychosis, preoperative sedation, control of seizures, and anesthetics. Short-acting barbiturates are also used as drugs of abuse. Barbiturate use has dramatically decreased since the 1970s with the introduction of benzodiazepines. 

Caffeine intoxication is the only official diagnosis associated with caffeinism in the DSM-IV-TR. Caffeine-induced anxiety may manifest as restlessness, nervousness, excitement, insomnia, diuresis, flushing, gastrointestinal disturbance, muscle twitching, irritability, and jitteriness. If caffeine-induced insomnia requires specific treatment, caffeine-induced sleep disorder (DSM-IV-TR) is an appropriate diagnosis." ... 

A patient who underwent renal transplantation was given ciclosporin 6 mg/kg daily by intravenous infusion over 2 hours and intravenous meth-ylprednisolone postoperatively. He also received patient-controlled analgesia (PCA) as bolus doses of morphine 0.5 mg to a total dose of 13 mg on the first day and 11 mg on the second day. On the third day he developed insomnia, anxiety, amnesia, aphasia and severe confusion. The morphine was discontinued and the symptoms subsided after treatment with propofol, diazepam and haloperidol. It was suggested that ciclosporin may have decreased the excitation threshold of neuronal cells, which potentiated the dysphoric effects of morphine. ... 

The definition of desired therapeutic and side effects in the case of the benzodiazepines very much depends on the clinical problem in question. The sedative and hypnotic actions are desired effects in the treatment of insomnia, but undesired effects in the treatment of anxiety disorders. Effects that are usually undesired include daytime drowsiness, potentiation of the sedative effects of ethanol, and anterograde amnesia. They are mediated via the benzodiazepine site of GABAa receptors, since they can be antagonized with flumazenil. 

Ciraulo DA, Jaffe JH Tricyclic antidepressants in the treatment of depression associated with alcoholism. Clin Psychopharmacol 1 146—150, 1981 Ciraulo DA, Nace E Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 9 276—284, 2000 Ciraulo DA, Barnhill JG, Jaffe JH, et al Intravenous pharmacokinetics of 2-hydroxy-imipramine in alcoholics and normal controls. J StudAlcohol 51 366-372, 1990 Ciraulo DA, Knapp CM, LoCastro J, et al A benzodiazepine mood effect scale reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 27 339—347, 2001 Collins MA Tetrahydropapaveroline in Parkinson s disease and alcoholism a look back in honor of Merton Sandler. Neurotoxicology 25 117-120, 2004 COMBINE Study Research Group Testing combined pharmacotherapies and behavioral interventions in alcohol dependence rationale and methods. Alcohol Clin Exp Res 27 1107-1122, 2003a... 

Venlafaxine extended release, in doses of 75 to 225 mg/day, improves social anxiety, performance, and avoidance behavior with a reduction in disability.61 Treatment with venlafaxine results in response rates similar to those seen with paroxetine.60 Venlafaxine may be effective in SSRI non-responders.62 As with SSRIs, doses should be tapered slowly when discontinuing therapy. Tolerability is similar to that observed in depression trials with venlafaxine extended release. Common side effects are anorexia, dry mouth, nausea, insomnia, and sexual dysfunction. 

Because Rohypnol is banned in the United States, there is an emerging trend for young people to start abusing two other Rohypnol-like drugs that are still legal in the United States clonazepam (Klonopin ) and alprazolam (Xanax). Both Klonopin and Xanax are benzodiazepines that are used for the treatment of anxiety and insomnia. Although they are less potent than Rohypnol, they can produce similar effects when mixed with alcohol and also have been reported to enhance the effects of heroin. 

No health hazards are known with the proper use of kava (Gruenwald et al. 1998). Kava has been approved by the German Commission E for treatment of anxiety and insomnia. In clinical studies of kava for anxiety, adverse effects were uncommon and did not differ across placebo and kava groups. There do not appear to be any studies published on the effects of acute overdosage with kava. Given its CNS depressant effects, it should not be taken with other similar drugs, including benzodiazepines, barbiturates. 

Aripiprazole (Abilify). Aripiprazole is indicated for the treatment of acute mania and for maintenance therapy. It is dosed at 5-30mg/day. Aripiprazole is well tolerated with the most common side effects being headache, agitation, anxiety, insomnia, and nausea. 

Alcohol. Along with several bromide preparations and paraldehyde, alcohol has often been used to relieve anxiety. Due to the marked untoward social and medical consequences of frequent use, alcohol has no place in the treatment of anxiety. Unfortunately, the inappropriate use of alcohol to self-medicate anxiety, depression, insomnia, or other symptoms often leads to alcoholism and therefore contributes to a signihcant public health problem. 

In contrast to panic disorder, the somewhat more subtle and persistent symptoms of GAD do not always command immediate attention. Although patients with GAD may present with a primary complaint of anxiety, they are more likely to complain of a physical ailment or another psychiatric condition or symptoms, for example, depression or insomnia. As such, many patients with GAD will seek treatment from a primary care physician long before recognizing the need for mental health care despite readily acknowledging that they have been anxious virtually all of their lives. 

Once chronic insomnia has developed, it hardly ever spontaneously resolves without treatment or intervention. The toll of chronic insomnia can be very high and the frustration it produces may precipitate a clinical depression or an anxiety disorder. Insomnia is also associated with decreased productivity in the workplace and more frequent use of medical services. Einally, substance abuse problems may result from the inappropriate use of alcohol or sedatives to induce sleep or caffeine and other stimulants to maintain alertness during the day. 

Insomnia Due to a Medical Illness. Medically ill patients often have trouble with insomnia. Acute insomnia is frequently precipitated by anxiety regarding the prognosis of the illness, pending test resnlts, or the anticipation of unpleasant treatments or diagnostic procednres. These sitnations can at times be the trigger that nltimately prodnces a chronic conrse of insomnia independent of the medical illness. 

A significant advantage of the benzodiazepines over other central nervous system depressants (e.g., the barbiturates) is that they possess a much greater separation between the dose that produces sleep and the dose that produces death. This increased margin of safety has been one of the major reasons benzodiazepines have largely replaced the barbiturates and other types of sedative-hypnotics in the treatment of anxiety and insomnia. In addition, benzodiazepine aclministration is associated with few side effects. 

---